Crossmark

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study

Crossref DOI link: https://doi.org/10.1007/s13300-020-00984-x

Published Online: 2020-12-26

Published Print: 2021-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jain, Akshay B. https://orcid.org/0000-0001-8515-5359
Kanters, Steve

Khurana, Reena

Kissock, Jagoda

Severin, Naomi

Stafford, Sara G.
Funding

Funding for this research was provided by:

Novo Nordisk Canada
License Information

Text and Data Mining valid from 2020-12-26

Version of Record valid from 2020-12-26
More Information

Article History

Received: 13 November 2020

Accepted: 11 December 2020

First Online: 26 December 2020

Document is current

Any future updates will be listed below